

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 5, 2017



AVALON  
GLOBOCARE CORP.

**AVALON GLOBOCARE CORP.**

(Exact name of registrant as specified in its charter)

Delaware

000-55709

47-1685128

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification Number)

83 South Street, Suite 101, Freehold, New Jersey 07728  
(Address of principal executive offices) (zip code)

646-762-4517

(Registrant's telephone number, including area code)

Copies to:

Stephen M. Fleming, Esq.

Fleming PLLC

49 Front Street, Suite 206

Rockville Centre, New York 11570

Phone: (516) 833-5034

Fax: (516) 977-1209

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01**      **Entry into a Material Definitive Agreement.**  
**Item 2.01**      **Completion of Acquisition or Disposition of Assets.**

On December 22, 2016, Avalon GloboCare Corp. (the "Company") entered into an Agreement of Sale (the "Purchase Agreement") with Freehold Craig Road Partnership ("Seller"), a New Jersey partnership, to purchase certain real property located in the Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9, Freehold, NJ 07798 (the "Property"). All rights under the Purchase Agreement were assigned by the Company to Avalon RT9 Properties, LLC, the Company's wholly owned subsidiary ("Avalon Properties"). Avalon Properties closed on the purchase of the Property on May 5, 2017. The purchase price including adjustments paid by the Company for the Property was \$7.65 million in cash. The Seller also assigned all lease agreements for all tenants on the Property to Avalon Properties.

The foregoing information is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full text of those agreements, each of which is attached an exhibit to this Current Report on Form 8-K. Readers should review those agreements for a complete understanding of the terms and conditions associated with this transaction.

**Item 9.01 Financial Statements and Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
10.1	Agreement of Sale by and between Freehold Craig Road Partnership, as Seller, and Avalon GloboCare Corp., as Buyer dated as of December 22, 2016 (1)
99.1	<a href="#">Press Release dated May 9, 2017</a>

(1) Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission dated December 23, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AVALON GLOBOCARE CORP.**

Dated: May 9, 2017

By: /s/ David Jin  
Name: David Jin  
Title: Chief Executive Officer, President and Director

---



### **Avalon GloboCare Corp. Completes Acquisition of Executive Center Property in Freehold, New Jersey**

Freehold, NJ — May 9, 2017- Avalon GloboCare Corp. (OTCQB: AVCO) ([www.avalon-globocare.com](http://www.avalon-globocare.com)), an intelligent cell-based biotechnology developer and healthcare service provider, announced today the completion of its purchase of the Freehold Executive Center, a three-story property located at 4400 Highway 9 in Freehold, New Jersey. The property, a modern 64,000 square foot class A office building, will serve as Avalon GloboCare's new worldwide headquarters and will continue to house the existing tenants. Archivista Realty, LLC and LaRocca, Hornik, Rosen, Greenberg and Blaha Esquires represented Avalon-GloboCare in the transaction.

David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare stated, "We are very pleased to have acquired this property as we feel it will be a valuable asset to Avalon, as a home for our management team, an attractive location for future talents to join our work force, and as an investment for our shareholders. We chose this particular site following a lengthy search as we felt that this location was geographically centered making the Company accessible to New York, New Jersey and Pennsylvania based healthcare providers, hospitals, pharmaceutical firms and major university research centers. This headquarters will serve as a key fundamental piece of our overall plan and act as a facilitator of our vision of continuing to build a global network of healthcare facilities and services for the medical communities we serve".

---

The company is planning a ribbon cutting ceremony and open house in the Third Quarter of 2017.

#### **ABOUT AVALON GLOBOCARE CORP.**

Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, disruptive cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely “Avalon Cell” and “Avalon Rehab.” In addition, AVCO provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. AVCO also engages in the management of stem cell banks and specialty clinical laboratories.

#### ***Forward-Looking Statements***

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

#### **Contact Information**

Avalon Globocare Corp.  
83 South Street, Suite 101  
Freehold, New Jersey 07728  
[PR@Avalon-GloboCare.com](mailto:PR@Avalon-GloboCare.com)

---